Ziopharm Oncology Inc., a maker of experimental cancer treatments, tumbled the most in seven years in New York trading after saying it would end plans to develop its lead drug candidate for soft tissue tumors.
Central-bank reserve shifts indicate the best foreign-exchange returns may be found by avoiding the “fading four” most-traded currencies in favor of the next tier, according to Samson Capital Advisors LLC.
Nomura Holdings Inc. trailed the world’s biggest investment banks last quarter in generating shareholder returns, underscoring the challenge for Chief Executive Officer Koji Nagai in trimming costs without sacrificing revenue.
Tax-exempt bonds are yielding more than Treasuries for the first time since the financial crisis, a relationship that history shows doesn’t last, especially as the Federal Reserve kindles inflation expectations.
An experimental drug from Ziopharm Oncology Inc. helped keep fast-growing sarcomas, lethal tumors that can grow to the size of basketballs, in check 77% longer than a standard treatment, a company-sponsored study found.